Summary of Haili Biotech's 2026 Semi-Annual Report
Shanghai Haili Biotechnology Co., Ltd. 2026 Semi-annual Report Summary Company Code: 603718 Company Abbreviation: *ST Haili
Shanghai Haili Biotechnology Co., Ltd.
2026 Interim Report Summary
Summary of the 2026 Semi-Annual Report of Shanghai Haili Biotechnology Co., Ltd.
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to www.sse.com.cn to read the full text of the semi-annual report carefully.
1.2 The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
1.3 All directors of the company shall attend the board meeting.
1.4 This semi-annual report has not been audited.
1.5 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
None
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation A shares before change Shanghai Stock Exchange *ST Haili 603718 Haili Biocontact and contact information Secretary of the board of directors Securities affairs representative
Name Pu Dongchan
Phone 021-60890892
No. 138, Huaihai Middle Road, Huangpu District, Shanghai
Office address
Room 805
Email [email protected]
2.2 Main financial data
Unit: Yuan Currency: RMB The end of the reporting period is compared with the end of the previous year The end of the reporting period The end of the previous year
Increase or decrease(%)
Total assets 1,379,571,744.79 1,125,109,601.59 22.62 shares attributable to listed companies
892,903,579.57 882,040,944.59 1.23 Dong’s net assets
This reporting period increased compared with the same period last year. The reporting period increased compared with the same period last year.
Less(%)
Operating income 135,891,431.63 109,776,927.64 23.79 Total profit 20,174,898.40 36,596,574.60 -44.87
Summary of the 2026 Semi-Annual Report of Shanghai Haili Biotechnology Co., Ltd.
Attributable to listed company shares
11,453,773.58 18,234,848.34 -37.19 Dong’s net profit
Attributable to listed company shares
Net profit after deducting non-recurring items 10,482,485.36 15,469,536.74 -32.24 profit and loss
Cash generated from business activities
22,549,147.61 38,120,676.82 -40.85 Net cash flow
weighted average net assets
1.28 1.16 Increase the profit rate by 0.12 percentage points (%)
Basic earnings per share (yuan/
0.01760 0.0282 -37.59 shares)
Diluted earnings per share (yuan/
0.01750 0.0276 -36.59
shares)
2.3 List of shareholdings of the top 10 shareholders
Unit: Shares Total number of shareholders as of the end of the reporting period (households) 28,723 Total number of preference shareholders (households) whose voting rights have been restored as of the end of the reporting period 0 Shareholding status of the top 10 shareholders
Limited holding
Shareholding ratio Shareholding Pledged, marked or frozen name of shareholder Nature of shareholder Conditions for sale
Example (%) Quantity Number of shares settled
Number of shares
Shanghai Haoyuan Venture Capital Development Co., Ltd. is a domestic non-state-owned company
34.70 226,197,938 0 Unlimited company Legal person
Zhang Haiming Domestic natural person 1.92 12,486,250 0 None Zhang Yue Domestic natural person 1.30 8,452,500 0 None Wang Min Domestic natural person 0.81 5,300,000 0 None UBS AG Overseas legal person 0.72 4,671,812 0 None MERRILLLYNCH
Overseas legal person 0.71 4,645,570 0 None INTERNATIONAL
Chen Nian Domestic natural person 0.60 3,918,000 0 None MORGANSTANLEY&
CO.INTERNATIONAL Overseas legal person 0.60 3,911,775 0 No PLC.
Shanghai Qianyi Investment Management Center
Domestic non-state-owned
(Limited partnership) - Qianyi Beiliang 0.54 3,546,860 0 None
legal person
No. 3 Private Securities Investment Fund
Hao Luo Domestic natural person 0.46 3,000,000 0 None
Explanation of the above-mentioned shareholder related relationships or concerted actions between Zhang Haiming, Zhang Yue and Shanghai Haoyuan Venture Capital Development Co., Ltd. There is a related relationship; in addition, related relationships between other shareholders
Unknown.
Preference shareholders whose voting rights have been restored and the number of shares they hold
None
Description
Summary of the 2026 Semi-Annual Report of Shanghai Haili Biotechnology Co., Ltd.
2.4 Total number of preference shareholders and top 10 preference shareholders as of the end of the reporting period
□Applicable √Not applicable
2.5 Changes in controlling shareholders or actual controllers
√Applicable □Not applicable
Name of new controlling shareholder Zhang Haiming
The name of the new actual controller is Zhang Haiming (unchanged)
Change date August 12, 2026 (note)
The Shanghai Stock Exchange website (www.sse.com.cn) disclosed on August 14, 2026:
Haili Biotech’s indicative announcement on the internal agreement between the controlling shareholder and its persons acting in concert to transfer the company’s shares and the change in the query index and date of the equity information disclosure website (announcement number: 2026-056)
Simplified Equity Change Report of Shanghai Haili Biotechnology Co., Ltd.
Acquisition report and summary of Shanghai Haili Biotechnology Co., Ltd.
Note: The company's controlling shareholder Shanghai Haoyuan Venture Capital Development Co., Ltd., the company's actual controller Zhang Haiming, and the person acting in concert Zhang Yue signed a "Share Transfer Agreement" on August 12, 2026. As of the disclosure date of this report, the relevant transfer procedures have not been completed.
2.6 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable